Perhaps in the context of HER2 overexpression and ER positivity, low or absent PgR expression may be a predictor of tumour dependence on HER2 activity and thus sensitivity to HER2 inhibition with agents such as lapatinib. This evidence concerns the gene ERBB2 and neoplasm.